Haixia Ding1, Zhen Huang2, Mengjie Chen2, Cheng Wang2, Xi Chen2, Jiangning Chen3, Junfeng Zhang4. 1. Department of Geriatric, Nanjing Medical University First Affiliated Hospital, No. 300, Guangzhou Road, Nanjing, China. 2. State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, China. 3. State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, China; State Key Laboratory of Analytical Chemistry for Life Sciences and Collaborative Innovation Center of Chemistry for Life Sciences, Nanjing University, Nanjing, China. Electronic address: jnchen@nju.edu.cn. 4. State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, China; State Key Laboratory of Analytical Chemistry for Life Sciences and Collaborative Innovation Center of Chemistry for Life Sciences, Nanjing University, Nanjing, China. Electronic address: jfzhang@nju.edu.cn.
Abstract
BACKGROUND AND OBJECTIVE: Parkinson's disease (PD) is the second most common age-related neurodegenerative disorder after Alzheimer's disease. The aim of this work was to determine whether the differences of serum miRNAs profiling could distinguish PD patients from healthy individuals. METHODS: We collected serum samples from 106 sporadic PD patients and 91 age/gender-matched healthy controls. Serum miRNAs were analysed by Solexa sequencing followed by a qRT-PCR examination. The qRT-PCR assay, which was divided into two phases, was used to validate the expression of miRNAs screened by Solexa sequencing. Receiver operating characteristic (ROC) curve analysis and clustering analysis were performed to determine the diagnostic usefulness of the selected miRNAs for PD. RESULTS: In this study, we generated a profile of 5 serum miRNAs: miR-195 was up-regulated, and miR-185, miR-15b, miR-221 and miR-181a were down-regulated. CONCLUSION: This group of five miRNAs can precisely distinguish PD patients from health individuals and may be used as a potential serum-based biomarker for the diagnosis of PD.
BACKGROUND AND OBJECTIVE:Parkinson's disease (PD) is the second most common age-related neurodegenerative disorder after Alzheimer's disease. The aim of this work was to determine whether the differences of serum miRNAs profiling could distinguish PDpatients from healthy individuals. METHODS: We collected serum samples from 106 sporadic PDpatients and 91 age/gender-matched healthy controls. Serum miRNAs were analysed by Solexa sequencing followed by a qRT-PCR examination. The qRT-PCR assay, which was divided into two phases, was used to validate the expression of miRNAs screened by Solexa sequencing. Receiver operating characteristic (ROC) curve analysis and clustering analysis were performed to determine the diagnostic usefulness of the selected miRNAs for PD. RESULTS: In this study, we generated a profile of 5 serum miRNAs: miR-195 was up-regulated, and miR-185, miR-15b, miR-221 and miR-181a were down-regulated. CONCLUSION: This group of five miRNAs can precisely distinguish PDpatients from health individuals and may be used as a potential serum-based biomarker for the diagnosis of PD.
Authors: Hanne Due; Pernille Svendsen; Julie Støve Bødker; Alexander Schmitz; Martin Bøgsted; Hans Erik Johnsen; Tarec Christoffer El-Galaly; Anne Stidsholt Roug; Karen Dybkær Journal: Biomed Res Int Date: 2016-05-16 Impact factor: 3.411